Skip to main content

Advertisement

Log in

Twenty-four-hour efficacy of preservative-free tafluprost for open-angle glaucoma patients, assessed by home intraocular pressure (Icare-ONE) and blood-pressure monitoring

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the effect of preservative-free (PF) tafluprost on diurnal variation of intraocular pressure (IOP) and ocular perfusion pressure (OPP), measured by use of home IOP and blood-pressure (BP) monitoring devices, for primary open angle glaucoma (POAG) patients.

Methods

Twenty-two eyes from 22 patients with POAG were studied. Initially, IOP was measured at the hospital by Goldmann applanation tonometry (GAT) and Icare-ONE rebound tonometry. Each patient was then instructed how to use the Icare-ONE and BP home monitoring devices. IOP and BP were measured at home by the patients, every 4 h, before and 2 weeks after once daily treatment with PF tafluprost (0.0015 %) ophthalmic solution.

Results

Intraclass correlations between different IOP measurements were greater than 0.8. PF tafluprost reduced mean diurnal IOP significantly for patients with POAG, from 15.7 ± 1.2 mmHg at baseline to 12.5 ± 0.6 mmHg 2 weeks after treatment (p < 0.001). It increased mean diurnal OPP from 48.5 ± 7.3 mmHg at baseline to 51.3 ± 7.0 mmHg post-treatment (p < 0.017).

Conclusions

Icare-ONE enables glaucoma patients to measure their own diurnal IOP fluctuations. Patient-measured Icare-ONE IOP readings showed that PF tafluprost effectively reduced diurnal IOP in eyes with POAG.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Leske MC. Open-angle glaucoma—an epidemiologic overview. Ophthalmic Epidemiol. 2007;14:166–72.

    Article  PubMed  Google Scholar 

  2. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–79.

    Article  PubMed  Google Scholar 

  3. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429–40.

    Article  Google Scholar 

  4. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13.

    Article  PubMed  Google Scholar 

  5. The American Academy of Ophthalmology Panel. Preffered practice pattern guidelines: primary open-angle glaucoma. The American Academy of Ophthalmology. 2010. http://one.aao.org/preferred-practice-pattern/primary-openangle-glaucoma-ppp--october-2010. Accessed 21 Nov 2014.

  6. Mills RP, Janz NK, Wren PA, Guire KE. Correlation of visual field with quality-of-life measures at diagnosis in the Collaborative Initial Glaucoma Treatment Study (CIGTS). J Glaucoma. 2001;10:192–8.

    Article  PubMed  CAS  Google Scholar 

  7. Hughes E, Spry P, Diamond J. 24-hour monitoring of intraocular pressure in glaucoma management: a retrospective review. J Glaucoma. 2003;12:232–6.

    Article  PubMed  Google Scholar 

  8. Kontiola A, Puska P. Measuring intraocular pressure with the pulsair 3000 and rebound tonometers in elderly patients without an anesthetic. Graefes Arch Clin Exp Ophthalmol. 2004;242:3–7.

    Article  PubMed  Google Scholar 

  9. Fernandes P, Diaz-Rey JA, Queiros A, Gonzalez-Meijome JM, Jorge J. Comparison of the ICare rebound tonometer with the Goldmann tonometer in a normal population. Ophthalmic Physiol Opt. 2005;25:436–40.

    Article  PubMed  CAS  Google Scholar 

  10. Martinez-de-la-Casa JM, Garcia-Feijoo J, Castillo A, Garcia-Sanchez J. Reproducibility and clinical evaluation of rebound tonometry. Invest Ophthalmol Vis Sci. 2005;46:4578–80.

    Article  PubMed  Google Scholar 

  11. Abraham LM, Epasinghe NC, Selva D, Casson R. Comparison of the ICare rebound tonometer with the Goldmann applanation tonometer by experienced and inexperienced tonometrists. Eye. 2008;22:503–6.

    Article  PubMed  CAS  Google Scholar 

  12. Asrani S, Chatterjee A, Wallace DK, Santiago-Turla C, Stinnett S. Evaluation of the ICare rebound tonometer as a home intraocular pressure monitoring device. J Glaucoma. 2011;20:74–9.

    Article  PubMed  Google Scholar 

  13. Takagi Y, Nakajima T, Shimazaki A, Kageyama M, Matsugi T, Matsumura Y, et al. Phamacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004;78:767–76.

    Article  PubMed  CAS  Google Scholar 

  14. Uusitalo H, Chen E, Pfeiffer N, Brignole-Baudouin F, Kaarniranta K, Leino M, et al. Switching from a preserved to a preservative-free prostaglandin preperation in topical glaucoma medication. Acta Ophthalmol. 2010;88:329–36.

    Article  PubMed  CAS  Google Scholar 

  15. Kuwayama Y, Nomura A. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety. Adv Ther. 2014;31:461–71.

    Article  PubMed  CAS  Google Scholar 

  16. Nakano T, Yoshikawa K, Kimura T, Suzumura H, Nanno M, Noro T. Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16 mmHg or less. Jpn J Ophthalmol. 2011;55:605–13.

    Article  PubMed  CAS  Google Scholar 

  17. Mizoguchi T, Ozaki M, Unoki K, Dake Y, Eto T, Arai M. A randomized crossover study comparing tafluprost 0.0015% with travoprost 0.004% in patients with normal-tension glaucoma (corrected). Clin Ophthalmol. 2012;6:1579–84.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  18. van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs-A meta-analysis of randomized clinical trials. Ophthalmology. 2005;112:1177–85.

    Article  PubMed  Google Scholar 

  19. Traverso CE, Ropo A, Papadia M, Uusitalo H. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of tafluprost compared with latanoprost. J Ocul Phamacol Ther. 2010;26:97–104.

    Article  CAS  Google Scholar 

  20. Sakata R, Shirato S, Miyata K, Aihara M. Incidence of deepening of the upper eyelid sulcus on treatment with a tafluprost ophthalmic solution. Jpn J Ophthalmol. 2014;58:212–7.

    Article  PubMed  CAS  Google Scholar 

  21. Chabi A, Varma R, Tsai JC, Lupinacci R, Pigeon J, Baranak C, et al. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2012;153:1187–96.

    Article  PubMed  CAS  Google Scholar 

  22. Konstas AG, Quaranta L, Katsanos A, Riva I, Tsai JC, Giannopoulos T, et al. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2013;97:1510–5.

    Article  PubMed  Google Scholar 

  23. Anderson DR, Patella VM. Automated static perimetry. 2nd ed. St. Louis: Mosby; 1999.

    Google Scholar 

  24. Drance SM, Crichton A, Mills RP. Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma. Am J Ophthalmol. 1998;125:585–92.

    Article  PubMed  CAS  Google Scholar 

  25. Li J, Herndon LW, Asrani SG, Stinnett S, Allingham RR. Clinical comparison of the proview eye pressure monitor with the Goldmann applanation tonometer and the tonopen. Arch Ophthalmol. 2004;122:1117–21.

    Article  PubMed  Google Scholar 

  26. Mansouri K, Shaarawy T. Continuous intraocular pressure monitoring with a wireless ocular telemetry sensor: initial clinical experience in patients with open angle glaucoma. Br J Ophthalmol. 2011;95:627–9.

    Article  PubMed  Google Scholar 

  27. Sahin A, Basmak H, Niyaz L, Yildirim N. Reproducibility and tolerability of the ICare rebound tonometer in school children. J Glaucoma. 2007;16:185–8.

    Article  PubMed  Google Scholar 

  28. Moreno-Montanes J, Martinez-de-la-Casa JM, Sabater AL, Morales L, Saenz C, Garcia-Feijoo J. Clinical evaluation of the new rebound tonometers Icare PRO and Icare ONE compared with the Goldmann tonometer. J Glaucoma. 2014. doi:10.1097/ijg.0000000000000058.

    Google Scholar 

  29. Rosentreter A, Jablonski KS, Mellein AC, Gaki S, Hueber A, Dietlein TS. A new rebound tonometer for home monitoring of intraocular pressure. Graefes Arch Clin Exp Ophthalmol. 2011;249:1713–9.

    Article  PubMed  Google Scholar 

  30. Halkiadakis I, Stratos A, Stergiopoulos G, Patsea E, Skouriotis S, Mitropoulos P, et al. Evaluation of the Icare-ONE rebound tonometer as a self-measuring intraocular pressure device in normal subjects. Graefes Arch Clin Exp Ophthalmol. 2012;250:1207–11.

    Article  PubMed  Google Scholar 

  31. Hommer A, Mohammed RO, Burchert M, Kimmich F. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma. Curr Med Res Opin. 2010;26:1905–13.

    Article  PubMed  CAS  Google Scholar 

  32. Rossi GC, Pasinetti GM, Raimondi M, Ricciardelli G, Scudeller L, Blini M, et al. Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naive ocular hypertension or glaucoma patients. Expert Opi Drug Saf. 2012;11:519–25.

    Article  CAS  Google Scholar 

  33. Hwang YH. Efficacy and tolerability of preservative-free tafluprost 0.0015% in Korean patients with glaucoma. Clin Ophthalmol. 2014;8:71–2.

    PubMed  PubMed Central  Google Scholar 

  34. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134–42.

    Article  PubMed  CAS  Google Scholar 

  35. Tsukahara S, Sasaki T. Postural change of IOP in normal persons and in patients with primary wide open-angle glaucoma and low-tension glaucoma. Br J Ophthalmol. 1984;68:389–92.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  36. Liu JH, Kripke DF, Twa MD, Hoffman RE, Mansberger SL, Rex KM, et al. Twenty-four-hour pattern of intraocular pressure in the aging population. Invest Ophthalmol Vis Sci. 1999;40:2912–7.

    PubMed  CAS  Google Scholar 

  37. Sakamoto M, Kanamori A, Fujihara M, Yamada Y, Nakamura M, Negi A. Assessment of IcareONE rebound tonometer for self-measuring intraocular pressure. Acta Ophthalmol. 2014;92:243–8.

    Article  PubMed  Google Scholar 

  38. Witte V, Glass A, Beck R, Guthoff R. Evaluation of the self-tonometer Icare ONE in comparison to Goldmann applanation tonometry. Ophthalmologe. 2012;109:1008–13.

    Article  PubMed  CAS  Google Scholar 

  39. Lee JY, Yoo C, Jung JH, Hwang YH, Kim YY. The effect of lateral decubitus position on intraocular pressure in healthy young subjects. Acta Ophthalmol. 2012;90:68–72.

    Article  Google Scholar 

  40. Lee JY, Yoo C, Kim YY. The effect of lateral decubitus position on intraocular pressure in patients with untreated open-angle glaucoma. Am J Ophthalmol. 2013;155:329–35.

    Article  PubMed  Google Scholar 

  41. Lee TE, Yoo C, Kim YY. Effects of different sleeping postures on intraocular pressure and ocular perfusion pressure in healthy young subjects. Ophthalmology. 2013;120:1565–70.

    Article  PubMed  Google Scholar 

  42. Kim KN, Jeoung JW, Park KH, Lee DS, Kim DM. Effect of lateral decubitus position on intraocular pressure in glaucoma patients with asymmetric visual field loss. Ophthalmology. 2013;120:731–5.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yong Yeon Kim.

Ethics declarations

Conflicts of interest

S. Y. Cho, None; Y. Y. Kim, None; C. Yoo, None; T. -E. Lee, None.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cho, S.Y., Kim, Y.Y., Yoo, C. et al. Twenty-four-hour efficacy of preservative-free tafluprost for open-angle glaucoma patients, assessed by home intraocular pressure (Icare-ONE) and blood-pressure monitoring. Jpn J Ophthalmol 60, 27–34 (2016). https://doi.org/10.1007/s10384-015-0413-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-015-0413-1

Keywords

Navigation